期刊文献+

羟基脲联合干扰素治疗糖尿病合并真性红细胞增多症疗效观察

Therapeutic Effect of Hydroxyurea Combined with Interferon on Diabetes Mellitus Complicated with Polycythemia Vera
下载PDF
导出
摘要 目的探讨羟基脲联合干扰素治疗糖尿病合并真性红细胞增多症的效果。方法选取该科2016年6月—2018年6月收治的42例糖尿病合并PV患者,随机分为两组,各21例,观察组采用羟基脲联合干扰素治疗,对照组采用羟基脲治疗。结果观察组总有效率为90.5%,显著高于对照组76.2%(P<0.05);两组FPG比较差异无统计学意义(P>0.05),观察组Hb、RBC、PLT、HCT较对照组显著下降(P<0.05)。结论羟基脲联合干扰素治疗糖尿病合并PV能有效抑制骨髓成纤维细胞的增殖,改善症状和预后。 Objective To investigate the effect of hydroxyurea combined with interferon in the treatment of diabetes complicated with polycythemia. Methods Forty-two patients with diabetes mellitus complicated with PV admitted to our department from June 2016 to June 2018 were randomly divided into two groups: 21 patients each. The observation group was treated with hydroxyurea combined with interferon, and the control group was treated with hydroxyurea. Results The total effective rate of the observation group was 90.5%, which was significantly higher than that of the control group (76.2%)(P<0.05). There was no difference in FPG between the two groups (P>0.05). The Hb, RBC, PLT and HCT of the observation group decreased significantly compared with the control group (P<0.05). Conclusion Hydroxyurea combined with interferon can effectively inhibit the proliferation of bone marrow fibroblasts and improve the symptoms and prognosis of diabetic patients with PV.
作者 崔璐 CUI Lu(Department of Hematology, Changchun Central Hospital, Changchun, Jilin Province, 130000 China)
出处 《糖尿病新世界》 2019年第7期73-74,共2页 Diabetes New World Magazine
关键词 羟基脲 干扰素 糖尿病 真性红细胞增多症 Hydroxyurea Interferon Diabetes Polycythemia
  • 相关文献

参考文献7

二级参考文献48

  • 1Tefferi A, Vardiman JW. Classification and diagnosis of my- eloproliferative neoplasms:the 2008 World Health Organiza- tion criteria and point-of-care diagnostic algorithms [ J ]. Leu- kemia,2008,22( 1 ) :14-22.
  • 2Titmarsh GJ, Duncombe AS, McMullin MF, et al. How com- mon are myeloproliferative neoplasms? A systematic review and meta-analysis[ J]. Am J Hematol,2014,89(6) :581-587.
  • 3Tefferi A. Essential thrombocythemia,polycythemia vera, and myelofibrosis:current management and the prospect of targe- ted therapy [ J]. Am J Hemato1,2008,83 (6) :491-497.
  • 4Finazzi G, Caruso V, Marchioli R, et al. Acute leukemia in pol- ycythemia vera:an analysis of 1638 patients enrolled in a pro- spective observational study [ J ]. Blood, 2005,105 ( 7 ) : 2664- 2670.
  • 5Marchioli R, Finazzi G, Specchia G, et al. Cardiovascular e- vents and intensity of treatment in polycythemia vera [ J ]. N Engl J Med,2013,368( 1 ) :22-33.
  • 6Landolfi R,Marchioli R,Kutti J, et al. Efficacy and safety of low-dose aspirin in polycythemia vera [ J ]. N Engl J Med, 2004,350(2) :114-124.
  • 7Alvarez-Larran A, Pereira A, Cervantes F, et al. Assessment and prognostic value of the European LeukemiaNet criteria for clinicohematologic response, resistance, and intolerance to hydroxyurea in polycythemia vera [ J ]. Blood, 2012,119 ( 6 ) : 1363-1369.
  • 8Tefferi A, Barbui T. Polycythemia vera and essential thrombo- cythemia: 2015 update on diagnosis, risk-stratification and management[ J]. Am J Hematol,2015,90(2) : 162-173.
  • 9James C, Ugo V, Le CJP, et al. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera [ J ]. Nature,2005,434 (7037) : 1144-1148.
  • 10Barosi G, Birgegard G, Finazzi G, et al. Response criteria for essential thrombocythemia and polycythemia vera:result of a European LeukemiaNet consensus conference [ J ]. Blood, 2009,113(20) :4829-4833.

共引文献30

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部